ArticlePhotoacoustics2022
Intraperitoneal administration for sustained photoacoustic contrast agent imaging.
Article in Photoacoustics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 12 citations in OpenAlex.
- Noninvasive whole-brain imaging of glymphatic dynamics.Science advances · 2026Article
- Review on Multispectral Photoacoustic Imaging Using Stimulated Raman Scattering Light Sources.Sensors (Basel, Switzerland) · 2025Review
- NIR-II Nanoprobes: A Review of Components-Based Approaches to Next-Generation Bioimaging Probes.Bioengineering (Basel, Switzerland) · 2023Review
- Multiscale photoacoustic tomography using reversibly switchable thermochromics.Journal of biomedical optics · 2023Article
- Barium sulfate and pigment admixture for photoacoustic and x-ray contrast imaging of the gut.Journal of biomedical optics · 2023Article
- Functional photoacoustic imaging: from nano- and micro- to macro-scale.Nano convergence · 2023Review
- Review on ultrasound-guided photoacoustic imaging for complementary analyses of biological systemsExperimental biology and medicine (Maywood, N.J.) · 2023Review
- Theoretical and experimental comparison of the performance of gold, titanium, and platinum nanodiscs as contrast agents for photoacoustic imaging.RSC advances · 2023Article
- Dual-Labelled Nanoparticles Inform on the Stability of Fluorescent Labels In Vivo.Pharmaceutics · 2023Article
- Recent Advances in Photoacoustic Agents for Theranostic Applications.Nanomaterials (Basel, Switzerland) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
Abstract
Photoacoustic (PA) imaging at 1064 nm in the second near-infrared (NIR-II) has attracted recent attention. We recently reported a surfactant-based formulation of a NIR-II dye (BIBDAH) for NIR-II PA contrast. Here, we investigated BIBDAH as a NIR-II PA contrast agent for longitudinal preclinical PA imaging. When administered to mice by the conventional intravenous (I.V.) route, BIBDAH was rapidly cleared from circulation, as indicated by a decrease in NIR-II absorption in sampled plasma. Conversely, when mice were injected with BIBDAH by the intraperitoneal (I.P.) route, peak NIR-II absorption levels in plasma were lower initially, but there was a sustained dye presence that resulted in a more consistent concentration of dye in plasma over 2 days. Increasing the I.P. injection dose and volume resulted in increased NIR-II area under the curve (AUC) in serum. Bimodal PA and ultrasound imaging reflected these results, showing a rapid decrease in PA signal in blood with I.V. administration, but permitting sustained imaging with I.P. administration. These results show that I.P. administration can be considered as an administration route in preclinical animal studies for improved longitudinal observation with more consistent contrast signal intensity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.